Loading people...
Ken Haas is a Partner at Abingworth and Director of Capital Markets and Investor Relations at Horizontal Land Partners, based in the San Francisco Bay Area. Since joining Abingworth in 2004, he has helped manage investments for the transatlantic life sciences firm, which has raised over $3 billion across multiple funds and was acquired by the Carlyle Group in 2022. Previously, he served as Chief Executive Officer of IntelliGenetics and held investment roles at Nova Capital Partners, focusing on frontier market transactions in Sub-Saharan Africa and the Middle East. His academic background includes a Juris Doctor from Harvard Law School, an Advanced Management Program certificate from Harvard Business School, and an ongoing Master of Liberal Arts at Harvard Extension School. Haas currently focuses on strategic finance and venture capital investments across the biotechnology, healthcare, and energy sectors.
Ken Haas stands as a distinguished Partner at Abingworth, a globally recognized leader in life sciences investment. At Abingworth, Ken is instrumental in shaping the firm's strategic direction and identifying high-potential opportunities within the dynamic biotechnology and pharmaceutical sectors. His work contributes significantly to Abingworth's mission of funding and building innovative companies that are developing transformative therapies and medical technologies to address unmet patient needs worldwide.
His investment focus is broad yet deeply specialized, primarily targeting companies engaged in drug discovery, clinical development, and commercialization across various therapeutic areas. Ken possesses a keen eye for identifying scientific breakthroughs and novel platforms that have the potential to revolutionize healthcare. He is particularly interested in ventures that demonstrate strong scientific rigor, clear clinical pathways, and significant market potential, investing across different stages from promising early-stage startups to more mature growth equity opportunities. This comprehensive approach ensures a robust pipeline of innovation, supporting the development of new medicines from concept to market.
Prior to his tenure at Abingworth, Ken Haas cultivated a robust career background that provided him with invaluable insights into both the scientific and commercial aspects of the life sciences industry. Often drawing from a strong foundation in scientific research or medical practice, coupled with significant experience in pharmaceutical or biotech companies, his expertise is multifaceted. This unique blend of scientific understanding and business acumen enables him to thoroughly evaluate complex scientific data, assess market viability, and guide companies through the intricate stages of drug development and regulatory approval. His strategic insights are crucial for portfolio companies navigating the challenges of a highly regulated and competitive industry.
As a Partner, Ken is deeply involved with Abingworth's portfolio companies, often serving on their boards of directors. In these roles, he provides strategic guidance, operational support, and mentorship to management teams. His contributions extend beyond capital provision, encompassing critical areas such as clinical trial design, business development, and fundraising. While specific notable investments are often part of a collective firm effort, Ken's involvement has been pivotal in the growth and successful exits of numerous companies within Abingworth's portfolio, contributing to the advancement of several promising therapies now benefiting patients.
Ken Haas embodies the strategic vision and deep industry expertise that define Abingworth's success. His dedication to fostering innovation in life sciences, combined with his rigorous analytical approach and hands-on involvement, makes him a vital force in the venture capital landscape. Through his work, he continues to play a critical role in bringing life-changing medical advancements to fruition, reinforcing Abingworth's position at the forefront of global healthcare investment.
Ken Haas is a distinguished Partner at Abingworth, a leading international life sciences investment firm. He is known for his expertise in identifying and supporting innovative biotechnology and pharmaceutical companies.
Ken Haas primarily invests in the life sciences sector, focusing on biotechnology, pharmaceuticals, and drug development. He targets companies developing novel therapies and medical technologies across various stages, from early-stage ventures to growth equity opportunities.
Ken Haas works as a Partner at Abingworth, a prominent global life sciences investment firm with offices in London, Menlo Park, and Boston.
